PROSPECT RP

The purpose of this study is to see if the drugs methotrexate, azathioprine, adalimumab, infliximab, and tocilizumab are effective in treating relapsing polychondritis (RP). The study has 2 stages. Participants enrolled in the first stage of the study will receive methotrexate or azathioprine (if there is a medical contraindication to methotrexate) for 6 months. If you are not responding to the drug at the end of 6 months, you will start stage 2 of the study. In stage 2, participants will receive either adalimumab, infliximab, or tocilizumab (if there is a medical contraindication to adalimumab or infliximab) for 6 months.  The choice between adalimumab vs infliximab will depend on availability and/or your preference between the adalimumab (a subcutaneous self-injecting drug vs infliximab (intravenous infusions administered at infusion centers). 

You may be eligible for this study if you meet the following criteria:

• Conditions: Medical Research, RP, relapsing polychrondritis
• Age: 99 years or below
• Gender: All